Company
Headquarters: London, United Kingdom
Employees: 6
CEO: Mr. Robert Rauker
Company | Market Cap (USD) |
---|---|
Abbott | $233.33 B |
Boston Scientific Corporation | $154.34 B |
Stryker | $151.06 B |
Medtronic | $113.25 B |
Edwards Lifesciences Corporation | $45.05 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Belluscura plc develops and commercialize oxygen related medical device products. The company offers X-PLO2R, a modular portable oxygen concentrator. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Last Financial Reports Date | June 30, 2023 |
Revenue TTM | £958,438 |
EBITDA | £-6,233,422 |
Gross Profit TTM | £68,105 |
Profit Margin | 4.87% |
Operating Margin | -1090.44% |
Quarterly Revenue Growth | -34.80% |
Belluscura plc has the following listings and related stock indices.
Stock: LSE: BELL wb_incandescent
Stock: FSX: 9VQ wb_incandescent